BAYERN JOSEPH sold $3K of CGC

BAYERN JOSEPH sold 3,197 shares of Canopy Growth Corp (CGC) at $0.92 on 2026-06-26.

Original reporting
SEC EDGAR · BAYERN JOSEPH
Published Jun 29, 2026, 8:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 29, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CGC
Neutral
medium confidence
Mentioned
$CGC
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CGCNeutralLow
01

Why it matters

A director open-market sale of 3,197 shares at $0.9237 was reported; the disclosure does not include any new corporate event beyond the transaction details.

02

Market read

Traders may monitor for follow-on insider activity, but this specific filing alone is unlikely to change valuation drivers.

03

What to watch

Insider sales are common and often not predictive; without context on total holdings, compensation, or prior sale patterns, the signal is weak.

Relevance 3/10Novelty 3/10Timing: after-hours/filing date (2026-06-29) for an insider sale disclosed on SEC EDGAR

Background

The article is an SEC Form 4 insider transaction disclosure for Canopy Growth Corp (CGC).

Company-level read

Ticker impact

$CGCNeutralMedium confidence
Context

Canopy Growth director Bayern Joseph filed a Form 4 open-market sale of 3,197 shares at $0.9237 on 2026-06-26.

Expected impact

Low likelihood of a sustained price move solely from this sale; any impact is likely short-lived.

Evidence & confidence

The filing is a director open-market sale with modest size and no stated new company event (no guidance, deal, or regulatory action).

Market effects

No sector read-through; this is a single-company insider transaction with no operational or regulatory catalyst.

None indicated.

None indicated.

Counterpoint

The sale could be non-informational (tax/portfolio rebalancing) and the filing notes no 10b5-1 plan, which can cut both ways for interpretation.

Key entities

  • Canopy Growth Corp

    Subject of the Form 4 insider transaction disclosure.

  • Bayern Joseph

    Director who sold 3,197 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CGCMed

Canopy Growth (CGC) Q2 2027 Earnings Call Transcript

Canopy Growth (CGC) reported Q2 2027 revenue of $81.4M, up 22% YoY, driven by 30% cannabis segment growth. Medical cannabis and international markets showed momentum, while Storz & Bickel revenue fell 44% YoY to $50.1M. The company expects improved yields and EU GMP certifications to boost growth and margins. Adjusted EBITDA loss narrowed to $2.9M, with a target of profitability in H2 2027.

$CGCMedAI 8/10

Canopy Growth Corporation Q2 2027 Earnings Call Summary

Canopy Growth reported Q2 2027 results, highlighting a 141% YoY increase in international cannabis revenue and a 44% decline in Storz & Bickel revenue due to economic uncertainty. The company aims for positive adjusted EBITDA in H2 2027, with cultivation improvements expected to boost flower production by 25-30% in early 2028. Canopy also secured EU GMP certification, enabling expansion into European markets beyond dry flower.

$CGCMed

Canopy Growth Q2 Earnings Call Highlights

Canopy Growth reported Q2 revenue growth in Canada and plans to build a dedicated sales force. Storz & Bickel revenue declined 4% but expects a strong Q3. Cultivation improvements aim for 25-30% yield increase. Adjusted gross margin fell to 31% from 33% due to VA reimbursement rate changes. Cash reserves were CAD 320 million as of September 30. The company may pursue a reverse stock split to maintain Nasdaq compliance.